Skip to main content
Erschienen in: World Journal of Surgery 12/2010

01.12.2010

Prognostic Significance of Ki-67 Labeling Index in Papillary Thyroid Carcinoma

verfasst von: Yasuhiro Ito, Akira Miyauchi, Kennichi Kakudo, Mitsuyoshi Hirokawa, Kaoru Kobayashi, Akihiro Miya

Erschienen in: World Journal of Surgery | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Ki-67 is a useful tool for evaluating cell proliferative activity in various tumors. Although the utility of Ki-67 labeling index (LI) to diagnose thyroid neoplasms has been investigated, little is known regarding the relationship between Ki-67 LI and the biological behavior of papillary thyroid carcinoma. In this study, we examined Ki-67 in 371 patients with papillary thyroid carcinoma to elucidate this issue.

Methods

A total of 371 patients with papillary carcinoma who underwent initial and locally curative surgery between 1996 and 1997 were enrolled in this study. We immunohistochemically investigated Ki-67 LI in their primary lesions and compared this finding with various clinicopathological features, including patient prognosis.

Results

Ki-67 LI was ≤1% in 213 patients (57%) and among the remaining 158, 35 showed Ki-67 LI >3%. Ki-67 LI was associated with patient age, massive extrathyroid extension, and distant metastasis at surgery. Of 363 patients without distant metastasis at surgery, 54 (15%) showed carcinoma recurrence during follow-up (average 124 months) and the disease-free survival (DFS) of patients with Ki-67 LI >1% was significantly worse than that of those with Ki-67 LI <1% (p < 0.0001). On multivariate analysis, Ki-67 LI was recognized as an independent prognostic factor for the DFS of patients. Although only eight patients died of carcinoma in our series, patients with Ki-67 LI >3% showed a significantly worse cause-specific survival (CSS) than those with Ki-67 LI <3% (p < 0.0001).

Conclusions

Careful evaluation of Ki-67 LI in primary lesions can predict DFS and CSS of patients with papillary thyroid carcinoma.
Literatur
1.
Zurück zum Zitat Ito Y, Miyauchi A (2009) Prognostic factors and therapeutic strategies for differentiated carcinoma of the thyroid. Endocr J 56:177–192CrossRefPubMed Ito Y, Miyauchi A (2009) Prognostic factors and therapeutic strategies for differentiated carcinoma of the thyroid. Endocr J 56:177–192CrossRefPubMed
2.
Zurück zum Zitat Ito Y, Tomoda C, Uruno T et al (2005) Ultrasound-detectable and anatomopathologically detectable node metastasis in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg 29:917–920CrossRefPubMed Ito Y, Tomoda C, Uruno T et al (2005) Ultrasound-detectable and anatomopathologically detectable node metastasis in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg 29:917–920CrossRefPubMed
3.
Zurück zum Zitat Ito Y, Tomoda C, Uruno T et al (2006) Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 30:780–786CrossRefPubMed Ito Y, Tomoda C, Uruno T et al (2006) Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 30:780–786CrossRefPubMed
4.
Zurück zum Zitat Ito Y, Kakudo K, Hirokawa M et al (2009) Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery 145:100–105CrossRefPubMed Ito Y, Kakudo K, Hirokawa M et al (2009) Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery 145:100–105CrossRefPubMed
5.
Zurück zum Zitat Cattoretti G, Becker MH, Key G et al (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357–363CrossRefPubMed Cattoretti G, Becker MH, Key G et al (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357–363CrossRefPubMed
6.
Zurück zum Zitat Wallin G, Backdahl M, Christensson B, Brimelius L, Atter G (1992) Nuclear protein content and Ki-67 immunoreactivity in nonneoplastic and neoplastic thyroid cells. Anal Quant Cytol Histol 14:296–303PubMed Wallin G, Backdahl M, Christensson B, Brimelius L, Atter G (1992) Nuclear protein content and Ki-67 immunoreactivity in nonneoplastic and neoplastic thyroid cells. Anal Quant Cytol Histol 14:296–303PubMed
7.
Zurück zum Zitat Basolo F, Pollina L, Fontanini G, Fiore L, Pacini F, Baldanzi A (1997) Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. Br J Cancer 75:537–541PubMed Basolo F, Pollina L, Fontanini G, Fiore L, Pacini F, Baldanzi A (1997) Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. Br J Cancer 75:537–541PubMed
8.
Zurück zum Zitat Besnick MB, Schacter P, Finkelstein Y, Kellner Y, Cohen O (1998) Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Mod Pathol 11:735–739 Besnick MB, Schacter P, Finkelstein Y, Kellner Y, Cohen O (1998) Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Mod Pathol 11:735–739
9.
Zurück zum Zitat Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV (1998) Expression of p27/kip 1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 11:169–174PubMed Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV (1998) Expression of p27/kip 1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 11:169–174PubMed
10.
Zurück zum Zitat Rickert D, Mitternayer C, Lindenfelser R, Biesterfeld S (2000) MIB-1 immunohistochemistry of follicular adenoma and follicular carcinoma of the thyroid gland. Anal Quant Cytol Histol 22:229–234PubMed Rickert D, Mitternayer C, Lindenfelser R, Biesterfeld S (2000) MIB-1 immunohistochemistry of follicular adenoma and follicular carcinoma of the thyroid gland. Anal Quant Cytol Histol 22:229–234PubMed
11.
Zurück zum Zitat Mehrotra P, Gonzalez MA, Johnson SJ et al (2006) Mcm-2 and Ki-67 have limited potential in preoperative diagnosis of thyroid malignancy. Laryngoscope 116:1434–1438CrossRefPubMed Mehrotra P, Gonzalez MA, Johnson SJ et al (2006) Mcm-2 and Ki-67 have limited potential in preoperative diagnosis of thyroid malignancy. Laryngoscope 116:1434–1438CrossRefPubMed
12.
Zurück zum Zitat Sobin LH, Wittekind CH (eds) (2002) UICC: TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York Sobin LH, Wittekind CH (eds) (2002) UICC: TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York
13.
Zurück zum Zitat Ito Y, Uruno T, Takamura Y et al (2005) Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology 68:87–96CrossRefPubMed Ito Y, Uruno T, Takamura Y et al (2005) Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology 68:87–96CrossRefPubMed
14.
Zurück zum Zitat Lim DJ, Baek KH, Lee YS et al (2007) Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma. Thyroid 17:883–888CrossRefPubMed Lim DJ, Baek KH, Lee YS et al (2007) Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma. Thyroid 17:883–888CrossRefPubMed
15.
Zurück zum Zitat Kjellman P, Wallin G, Hoog A, Auer G, Larsson C, Zadenius J (2003) MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma? Thyroid 13:371–380CrossRefPubMed Kjellman P, Wallin G, Hoog A, Auer G, Larsson C, Zadenius J (2003) MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma? Thyroid 13:371–380CrossRefPubMed
16.
Zurück zum Zitat Siironen P, Louhimo J, Nordling S et al (2005) Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol 26:57–64CrossRefPubMed Siironen P, Louhimo J, Nordling S et al (2005) Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol 26:57–64CrossRefPubMed
17.
Zurück zum Zitat Sofiadis A, Tani E, Foukakis T et al (2009) Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy. Int J Oncol 35:369–374PubMed Sofiadis A, Tani E, Foukakis T et al (2009) Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy. Int J Oncol 35:369–374PubMed
18.
Zurück zum Zitat Gunia S, Albrescht K, Koch S et al (2008) Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 26:243–250CrossRefPubMed Gunia S, Albrescht K, Koch S et al (2008) Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 26:243–250CrossRefPubMed
19.
Zurück zum Zitat Preusser M, Heinzi H, Gelpi E et al (2008) Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 53:39–47CrossRefPubMed Preusser M, Heinzi H, Gelpi E et al (2008) Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 53:39–47CrossRefPubMed
20.
Zurück zum Zitat El AH, Esmail E, Abbas M, Ouf K (2001) MIB-1 index, S-phase fraction, mitotic figure count, and SBR histological grading in invasive breast carcinoma: a comparative study. Breast J 7:106–110CrossRef El AH, Esmail E, Abbas M, Ouf K (2001) MIB-1 index, S-phase fraction, mitotic figure count, and SBR histological grading in invasive breast carcinoma: a comparative study. Breast J 7:106–110CrossRef
21.
Zurück zum Zitat Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tan EM (1986) Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 166:209–219CrossRefPubMed Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tan EM (1986) Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 166:209–219CrossRefPubMed
22.
Zurück zum Zitat Hoyt JW, Gown AM, Kim DK, Berger MS (1995) Analysis of proliferative grade in glial neoplasms using antibodies to the Ki-67 defined antigen and PCNA in formalin fixed, deparaffinized tissues. J Neurooncol 24:183–189CrossRef Hoyt JW, Gown AM, Kim DK, Berger MS (1995) Analysis of proliferative grade in glial neoplasms using antibodies to the Ki-67 defined antigen and PCNA in formalin fixed, deparaffinized tissues. J Neurooncol 24:183–189CrossRef
23.
Zurück zum Zitat Sullivan RP, Mortimer G, Murschertaigh IO (1993) Cell proliferation in breast tumours: analysis of histological parameters Ki67 and PCNA expression. Ir J Med Sci 162:343–347CrossRefPubMed Sullivan RP, Mortimer G, Murschertaigh IO (1993) Cell proliferation in breast tumours: analysis of histological parameters Ki67 and PCNA expression. Ir J Med Sci 162:343–347CrossRefPubMed
24.
Zurück zum Zitat Pelosi G, Bresaola E, Manfrin E, Rodella S, Schiavon I, Iannucci A (1994) Immunocytochemical detection of cell proliferation-related antigens in cytologic smears of human malignant neoplasms u sing PC10, reactive with proliferating cell nuclear antigen, and Ki-67. A comparative study. Arch Pathol Lab Med 118:510–516PubMed Pelosi G, Bresaola E, Manfrin E, Rodella S, Schiavon I, Iannucci A (1994) Immunocytochemical detection of cell proliferation-related antigens in cytologic smears of human malignant neoplasms u sing PC10, reactive with proliferating cell nuclear antigen, and Ki-67. A comparative study. Arch Pathol Lab Med 118:510–516PubMed
25.
Zurück zum Zitat Marais R, Marshall CJ (1996) Control of the ERK MAP kinase cascade by Ras and Raf. In: Parker PJ, Pawson T (eds) Cell signaling. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 101–125 Marais R, Marshall CJ (1996) Control of the ERK MAP kinase cascade by Ras and Raf. In: Parker PJ, Pawson T (eds) Cell signaling. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 101–125
26.
Zurück zum Zitat Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25–40PubMed Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25–40PubMed
27.
Zurück zum Zitat MacCorkle RA, Tan TH (2005) Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 43:451–461CrossRefPubMed MacCorkle RA, Tan TH (2005) Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 43:451–461CrossRefPubMed
28.
Zurück zum Zitat Kim TY, Kim WB, Rhee YS et al (2006) The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 65:364–368CrossRef Kim TY, Kim WB, Rhee YS et al (2006) The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 65:364–368CrossRef
29.
Zurück zum Zitat Fugazzola L, Peuxeddu E, Avenia N et al (2006) Correlation between B-RAFV600E mutation and clinicopathologic parameters in papillary thyroid carcinoma: data from a multicentric Italia study and review of the literature. Endcr Relat Cancer 13:455–464CrossRef Fugazzola L, Peuxeddu E, Avenia N et al (2006) Correlation between B-RAFV600E mutation and clinicopathologic parameters in papillary thyroid carcinoma: data from a multicentric Italia study and review of the literature. Endcr Relat Cancer 13:455–464CrossRef
30.
Zurück zum Zitat Xing M, Westra WH, Tufano RP et al (2005) BRAF mutation predicts poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373–6379CrossRefPubMed Xing M, Westra WH, Tufano RP et al (2005) BRAF mutation predicts poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373–6379CrossRefPubMed
31.
Zurück zum Zitat Lupi C, Glannini R, Ugolini C et al (2007) Association of BRAF V600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92:4085–4090CrossRefPubMed Lupi C, Glannini R, Ugolini C et al (2007) Association of BRAF V600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92:4085–4090CrossRefPubMed
32.
Zurück zum Zitat Nakayama H, Yoshida A, Nakamura Y et al (2007) Clinical significance of BRAF(V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 27:3645–3649PubMed Nakayama H, Yoshida A, Nakamura Y et al (2007) Clinical significance of BRAF(V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 27:3645–3649PubMed
33.
Zurück zum Zitat Ito Y, Yoshida H, Maruo R et al (2009) BRAF mutation in papillary thyroid carcinoma in Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56:89–97CrossRefPubMed Ito Y, Yoshida H, Maruo R et al (2009) BRAF mutation in papillary thyroid carcinoma in Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56:89–97CrossRefPubMed
Metadaten
Titel
Prognostic Significance of Ki-67 Labeling Index in Papillary Thyroid Carcinoma
verfasst von
Yasuhiro Ito
Akira Miyauchi
Kennichi Kakudo
Mitsuyoshi Hirokawa
Kaoru Kobayashi
Akihiro Miya
Publikationsdatum
01.12.2010
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 12/2010
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-010-0746-3

Weitere Artikel der Ausgabe 12/2010

World Journal of Surgery 12/2010 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.